CDK4 and breast cancer: Thus, we next evaluated the effects of KIFC2 on cellular sensitivity of HR+/HER2– BC to the most-used ET drug, Tam, and the FDA/EMA-approved CDK4/6 inhibitors Abema and Palbo (10).